Format

Send to

Choose Destination
Can J Cardiol. 2015 Oct;31(10):1293-302. doi: 10.1016/j.cjca.2015.03.023. Epub 2015 Mar 25.

suPAR: A New Biomarker for Cardiovascular Disease?

Author information

1
Department of Medicine, Glostrup Hospital, University of Copenhagen, Glostrup, Denmark. Electronic address: gethin.william.hodges@regionh.dk.
2
Department of Medicine, Glostrup Hospital, University of Copenhagen, Glostrup, Denmark.
3
Department of Medicine, Glostrup Hospital, University of Copenhagen, Glostrup, Denmark; Department of Cardiology, Faculty of Health, Örebro University, Örebro, Sweden.
4
Clinical Research Centre, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark.

Abstract

The fundamental role of inflammation in cardiovascular disease (CVD) has prompted interest in numerous biomarkers that detect subclinical levels of inflammation. Soluble urokinase plasminogen activator receptor (suPAR) is a novel biomarker that correlates significantly with cardiovascular events and outperforms traditional markers of inflammation such as C-reactive protein (CRP) in prognosticating a range of CVDs. Furthermore, of particular interest is the suggestion that suPAR reflects a pathophysiological pathway more closely linked with subclinical organ damage than CRP. We provide the first comprehensive review of suPAR in CVD and explore its function and usefulness in predicting cardiovascular events.

Comment in

PMID:
26118447
DOI:
10.1016/j.cjca.2015.03.023
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center